Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-0653, ezetimibe · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| MK-0653, ezetimibe | DRUG | - |
| Duration of Treatment: 3 months | DRUG | - |
Inclusion Criteria: * Primary hypercholesterolemia treated with any statin at any dose, for at least 3 months with a ldl cholesterol above 115 mg/dl (esc 2003 recommendations). Exclusion Criteria: * pregnant or breast feeding women * Lipid-lowering agents including hmg-coa reductase inhibitors ot...
MK-0653, also known as ezetimibe, is used for hypercholesterolemia, including conditions like mixed hyperlipidemia and elevated cholesterol with coronary heart disease. It is being developed for lipid metabolism disorders and is in Phase 3 clinical trials.
MK-0653 targets cholesterol absorption in the intestine. It is a small molecule that inhibits the absorption of cholesterol from the diet, thereby lowering blood cholesterol levels. This mechanism is relevant for treating hypercholesterolemia and related lipid disorders.
MK-0653 is being developed by Organon & Co., a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol OGN. The company is conducting Phase 3 clinical trials for this drug.
MK-0653 is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. All nine clinical trials for MK-0653 have been completed, with no active trials currently ongoing.
MK-0653 has been studied in several Phase 3 clinical trials, including NCT00092560, NCT00092573, NCT00092599, and NCT00092612. These trials enrolled patients with hypercholesterolemia, hypertriglyceridemia, and coronary heart disease, with a total enrollment of over 6,000 participants.
Yes, MK-0653 is also known as ezetimibe. This alternative name is used in clinical trial titles and medical literature. Ezetimibe is the generic name for this cholesterol-lowering medication.